Bosun Asset Management LLC Lowers Holdings in ADMA Biologics Inc $ADMA

Key Points

• Bosun Asset Management LLC reduced its holdings in ADMA Biologics Inc by 50.9% during the first quarter, owning 31,660 shares worth approximately $628,000 after selling 32,810 shares.
• The institution saw significant activity from other hedge funds, with Nuveen LLC establishing a new position worth about $93.5 million and MetLife Investment Management LLC increasing its holdings by 714.1% during the same quarter.
• ADMA Biologics reported earnings of $0.15 per share for the recent quarter, exceeding expectations, with a revenue increase of 13.8% year-over-year.

Bosun Asset Management LLC cut its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 50.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,660 shares of the biotechnology company's stock after selling 32,810 shares during the period. Bosun Asset Management LLC's holdings in ADMA Biologics were worth $628,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ardsley Advisory Partners LP purchased a new position in ADMA Biologics during the 1st quarter valued at $5,952,000. PDT Partners LLC bought a new stake in shares of ADMA Biologics during the 1st quarter valued at about $1,476,000. Cubist Systematic Strategies LLC increased its position in shares of ADMA Biologics by 26.0% during the first quarter. Cubist Systematic Strategies LLC now owns 483,797 shares of the biotechnology company's stock valued at $9,599,000 after buying an additional 99,721 shares during the period. Royal Bank of Canada raised its stake in ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company's stock worth $1,903,000 after buying an additional 50,801 shares in the last quarter. Finally, Vident Advisory LLC bought a new position in ADMA Biologics in the first quarter worth about $2,735,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Activity at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the sale, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 425,621 shares of company stock worth $8,829,333. Insiders own 3.50% of the company's stock.

ADMA Biologics Stock Up 0.3%

ADMA Biologics stock traded up $0.05 during trading hours on Tuesday, hitting $16.47. 1,578,916 shares of the stock traded hands, compared to its average volume of 3,128,042. ADMA Biologics Inc has a one year low of $13.50 and a one year high of $25.67. The firm's 50-day moving average price is $17.63 and its two-hundred day moving average price is $18.97. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.93 billion, a PE ratio of 19.11 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.13 EPS. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.